Real-World Evidence in Pharmaceutical Development: Generating Value Beyond the Trial

Randomized controlled trials remain the gold standard for demonstrating efficacy and safety, but they cannot answer every question that regulators, payers, clinicians and patients have. Trials enroll selected populations under controlled conditions, run for limited durations and may not reflect how medicines perform in routine care. Real-world evidence (RWE), derived from real-world data (RWD) collected outside traditional trials, complements trial findings and increasingly supports decision-making across the product lifecycle. This white paper examines data sources, study design, quality standards and applications of RWE in pharmaceutical development.

What Is Real-World Evidence?

Real-world data are data relating to patient health status or the delivery of healthcare collected from sources such as electronic health records, claims databases, disease and product registries, wearable devices and patient-reported outcomes. RWE is the clinical evidence about the use and potential benefits or risks of a medical product derived from analysis of RWD. Legislation such as the 21st Century Cures Act in the United States has encouraged regulators to consider RWE, and agencies in Europe and elsewhere have published frameworks and guidance.

Data Sources and Their Characteristics

Electronic Health Records

EHRs contain rich clinical detail such as diagnoses, laboratory results, medications and notes, reflecting real clinical practice. Challenges include inconsistent data capture, missing information and fragmentation across health systems. Natural language processing can extract information from unstructured notes.

Claims and Administrative Databases

Claims data provide large populations and longitudinal records of prescriptions, procedures and costs, useful for utilization, adherence and economic analyses. They lack clinical detail such as disease severity or laboratory values.

Registries

Disease and product registries collect structured data on defined populations over time, often including outcomes of interest. They are especially valuable in rare diseases and for long-term safety follow-up.

Patient-Generated and Digital Data

Wearables, mobile apps and patient-reported outcomes capture symptoms and function between clinic visits, providing a more complete picture of daily life with a condition.

• •Combine multiple sources to balance depth and breadth
• •Assess data provenance, completeness and coding standards
• •Consider linkage across sources with appropriate privacy protections

Designing Rigorous Real-World Studies

Fit-for-Purpose Data

Data must be relevant and reliable for the research question. Assessing whether the data capture the exposure, outcome and confounders needed is the first step. A feasibility assessment prior to protocol finalization avoids wasted effort.

Study Design and Bias Control

Observational studies are vulnerable to confounding, selection bias and information bias. Design approaches include new-user active-comparator designs, propensity score methods, inverse probability weighting, instrumental variables and sensitivity analyses to quantify the impact of unmeasured confounding. Target trial emulation applies the principles of randomized trial design to observational data, specifying eligibility, treatment strategies, time zero and outcomes explicitly.

Pragmatic and Hybrid Trials

Pragmatic trials embed randomization in routine care, generating evidence in real-world settings. Hybrid designs combine trial data with external real-world controls, particularly useful where randomization is difficult.

Transparency

Pre-registering protocols and statistical analysis plans, documenting data transformations and sharing code enhance credibility. Regulators and journals increasingly expect such transparency.

Applications Across the Lifecycle

Development and Regulatory Decisions

RWE informs disease understanding, trial design and feasibility, patient identification and external control arms for single-arm studies. In some cases, it supports label expansions and post-approval requirements. Regulators have accepted RWE in decisions on new indications, especially when randomized trials are impractical.

Safety Monitoring

Post-marketing surveillance using large databases detects rare adverse events not seen in trials and characterizes risk in subgroups such as older adults or pregnant women.

Access and Reimbursement

Payers use RWE to evaluate comparative effectiveness, budget impact and cost-effectiveness. Outcomes-based contracts rely on real-world measurement of performance.

Commercial and Medical Strategy

Understanding treatment patterns, unmet needs and adherence guides medical education and patient support programs.

Data Quality, Governance and Privacy

Quality Frameworks

Assessing accuracy, completeness, consistency, timeliness and traceability ensures reliability. Common data models, such as OMOP, standardize structure and vocabularies, enabling reproducible analytics across databases.

Privacy and Ethics

Compliance with data protection regulations such as HIPAA and GDPR is essential. De-identification, secure environments, consent and governance structures protect individuals. Patient involvement in research design builds trust.

Challenges and Limitations

Limitations include residual confounding, variable data quality and difficulty generalizing across health systems. Transparent acknowledgement of limitations and triangulation with other evidence strengthen conclusions. Investing in data infrastructure, skilled analysts and partnerships is required.

Building an RWE Capability

• •Define strategic questions that RWE can answer
• •Establish governance for data access, quality and privacy
• •Develop methodological expertise in causal inference
• •Engage regulators early to align on study design
• •Plan evidence generation across the product lifecycle

Conclusion

Real-world evidence extends the value of clinical trials by showing how medicines perform in everyday practice. With fit-for-purpose data, rigorous methods and transparent reporting, RWE supports better decisions for regulators, payers, clinicians and patients.